Schneyer Mark C. — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Schneyer Mark C. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.25M.

Profile

Schneyer Mark C.

Mark C. Schneyer is the Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc, a biopharmaceutical company focused on CNS disorders. He has been involved in multiple SEC filings related to his role at the company.

RoleInsider
Notability30/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-05-05ACADACADIA PHARMACEUTICALS INCS — Open-market sale3.5K$21.79$76K
2026-05-05ACADACADIA PHARMACEUTICALS INCM — Option exercise6.8K—
2026-04-07ACADACADIA PHARMACEUTICALS INCS — Open-market sale [10b5-1]2.7K$22.20$60K
2026-04-07ACADACADIA PHARMACEUTICALS INCM — Option exercise [10b5-1]5.3K—
2026-03-27ACADACADIA PHARMACEUTICALS INCS — Open-market sale [10b5-1]37$21.72$804
2026-03-27ACADACADIA PHARMACEUTICALS INCS — Open-market sale [10b5-1]3.2K$21.65$69K
2026-03-27ACADACADIA PHARMACEUTICALS INCM — Option exercise [10b5-1]6.2K—
2026-03-27ACADACADIA PHARMACEUTICALS INCS — Open-market sale [10b5-1]4.2K$21.47$90K
2026-03-27ACADACADIA PHARMACEUTICALS INCM — Option exercise [10b5-1]8.1K—
2025-09-12ACADACADIA PHARMACEUTICALS INCS — Open-market sale3.5K$23.65$83K
2025-09-12ACADACADIA PHARMACEUTICALS INCA — Grant or award6.8K$0.00
2025-08-18ACADACADIA PHARMACEUTICALS INCS — Open-market sale22.0K$25.18$554K
2025-05-16ACADACADIA PHARMACEUTICALS INCS — Open-market sale2.0K$25.00$50K
2025-05-01ACADACADIA PHARMACEUTICALS INCS — Open-market sale3.5K$14.60$51K
2025-05-01ACADACADIA PHARMACEUTICALS INCM — Option exercise6.8K—
2025-04-05ACADACADIA PHARMACEUTICALS INCS — Open-market sale2.7K$14.82$40K
2025-04-05ACADACADIA PHARMACEUTICALS INCM — Option exercise5.3K—
2024-11-19ACADACADIA PHARMACEUTICALS INCS — Open-market sale [10b5-1]10.3K$16.81$172K
2024-11-19ACADACADIA PHARMACEUTICALS INCM — Option exercise [10b5-1]9.9K—
2024-11-19ACADACADIA PHARMACEUTICALS INCM — Option exercise [10b5-1]9.9K—

Companies — Last 90 Days

Frequently Asked Questions

Who is Schneyer Mark C.?

Mark C. Schneyer is the Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc, a biopharmaceutical company focused on CNS disorders. He has been involved in multiple SEC filings related to his role at the company.…

How many SEC Form 4 filings has Schneyer Mark C. submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Has Schneyer Mark C. been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 11 open-market sales ($1.25M) across all tracked filings.

Where can I see all of Schneyer Mark C.'s SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Schneyer Mark C. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.